

John T Randolph

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/739677/publications.pdf>

Version: 2024-02-01

9
papers

322
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

537
citing authors

#	ARTICLE	IF	CITATIONS
1	Desymmetrization of pibrentasvir for efficient prodrug synthesis. <i>Chemical Science</i> , 2021, 12, 10076-10082.	7.4	5
2	Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11034-11044.	6.4	9
3	HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments. <i>Topics in Medicinal Chemistry</i> , 2019, , 133-156.	0.8	1
4	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4052-4066.	6.4	42
5	Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1153-1163.	6.4	17
6	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	117
7	Discovery of fluorobenzimidazole HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5462-5467.	2.2	5
8	Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2047-2057.	6.4	120
9	High potency improvements to weak aryl uracil HCV polymerase inhibitor leads. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4367-4369.	2.2	6